menu
    • menu
    [{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Lucid Psycheceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Undisclosed","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Lucid Psycheceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Lucid Psycheceuticals"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu CRO","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Ingenu CRO","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Ingenu CRO"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FSD201","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FSD201","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ iNGENu","highestDevelopmentStatusID":"8","companyTruncated":"Quantum BioPharma \/ iNGENu"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FSD-F2R6-A-CP","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Quantum BioPharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Quantum BioPharma

    Menu

    Quantum BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Ingenu

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            iNGENu, Quantum BioPharma to Launch Australian Trial for Chronic Nociplastic Pain

                            Details : Quantum BioPharma is advancing FSD202, an ultra-micronized PEA therapy, into a Phase 2 trial targeting chronic nociplastic pain in MCAS patients, addressing neuroimmune-driven pain.

                            Product Name : FSD202

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 04, 2025

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Ingenu

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quantum Biopharma Begins Dosing of Second Cohort in Lucid-21-302 Phase 1 Trial

                            Details : Lucid-21-302, a first-in-class, non-immunomodulatory, neuroprotective compound with hypercitrullination inhibition as unique mechanism of action is being investigated for multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quantum Doses First Sentinel for Phase 1 Lucid-21-302 Trial in Australia

                            Details : Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).

                            Product Name : Lucid-MS

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 29, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ingenu CRO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Quantum Biopharma Partners with Ingenu CRO For Multiple Sclerosis Study

                            Details : Ingenu will conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis facilitating a future phase 2 with Lucid-21-302 (Lucid-MS).

                            Product Name : Lucid-MS

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ingenu CRO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FSD-F2R6-A-CP

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication

                            Details : FSD-F2R6-A-CP is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Alcoholic Intoxication.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 17, 2024

                            Lead Product(s) : FSD-F2R6-A-CP

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Lucid Psycheceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteer...

                            Details : Lucid-21-302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 20, 2023

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Lucid Psycheceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FSD201

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

                            Details : FSD201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mast Cell Activation Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : FSD201

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FSD201

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

                            Details : FSD201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 06, 2020

                            Lead Product(s) : FSD201

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth